New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
The use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy.Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the...
Main Authors: | Ana G. Almeida, António Almeida, Teresa Melo, Lurdes Guerra, Luís Lopes, Patrícia Ribeiro, Marta Duarte, Alexandra Mota, Ricardo Fontes-Carvalho |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Revista Portuguesa de Cardiologia (English Edition) |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2174204919300054 |
Similar Items
-
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
by: IL Davydkin, et al.
Published: (2018-10-01) -
Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01) -
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review
by: Marco Santoro, et al.
Published: (2021-07-01) -
Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors
by: N. Lopina, et al.
Published: (2020-10-01) -
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)